Clinical features of pulmonary arterial hypertension in patients receiving dasatinib

American Journal of Hematology

Volumn 90, Issue 11, 2015, Pages 1060-1064

  Shah, Neil P ^a   Wallis, Nicola ^b   Farber, Harrison W ^c   Mauro, Michael J ^d   Wolf, Robert A ^b   Mattei, Daniele ^e   Guha, Mausumee ^b   Rea, Delphine ^f   Peacock, Andrew ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e S CROCE E CARLE HOSPITAL   (Italy)

^f SAINT LOUIS HOSPITAL   (France)

^g Scottish Pulmonary Vascular Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DASATINIB; HYDROXYUREA; IMATINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; FATIGUE; FEMALE; FLUID RETENTION; FOLLOW UP; HEART CATHETERIZATION; HUMAN; LUNG FUNCTION TEST; MALE; MEDICAL HISTORY; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PLEURA EFFUSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK FACTOR; CHEMICALLY INDUCED; FACTUAL DATABASE; HYPERTENSION, PULMONARY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARDIAC CATHETERIZATION; DASATINIB; DATABASES, FACTUAL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS;

EID: 84944522481     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24174     Document Type: Article

References (34)

1. Bristol-Myers Squibb Co. Sprycel Prescribing Information. Princeton, NJ; 2014.
2. Novartis Pharmaceutical Corp. Gleevec Prescribing Information. East Hanover, NJ; 2015.
3. Novartis Pharmaceutical Corp. Tasigna Prescribing Information. East Hanover, NJ; 2015.
4. Mattei D, Feola M, Orzan F, et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009; 43:967-968.
5. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009; 33:861-864.
6. Hennigs JK, Keller G, Baumann HJ, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 2011; 11:30.
7. Dumitrescu D, Seck C, Ten Freyhaus H, et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 2011; 38:218-220.
8. Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125:2128-2137.
9. Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res 2012; 36:e4-e6.
10. Sano M, Saotome M, Urushida T, et al. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia: critical alert. Intern Med 2012; 51:2337-2340.
11. Philibert L, Cazorla C, Peyrière H, et al. Pulmonary arterial hypertension induced by dasatinib: positive reintroduction with nilotinib. Fundam Clin Pharmacol 2011 ;25(suppl S1):476.
12. Galiè N, Hoeper MM, Humbert M, et al. ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30:2493-2537. Erratum in: Eur Heart J 2011; 32:926.
13. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53:1573-1619 and Circulation 2009; 119:2250-2294. Erratum in: Circulation 2009; 120:e13.
14. Simonneau G, Gatzoulis MA, Adiata I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62:D34-D41. Erratum in: J Am Coll Cardiol 2014; 63:746.
15. Peacock AJ, Murphy NF, McMurray JJV, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30:104-109.
16. Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension. Chest 2012; 141:210-121.
17. Wilkins MR. Pulmonary hypertension: The science behind the disease spectrum. Eur Respir Rev 2012; 21:19-26.
18. de Jesus Perez V, Kudelko K, Snook S, Zamanian RT. Drugs and toxins-associated pulmonary arterial hypertension: Lessons learned and challenges ahead. Int J Clin Pract 2011; 65:8-10.
19. Fruehauf S, Steiger S, Topaly J. Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous leukemia. Ann Hematol 2001; 80:308-310.
20. Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study. Circulation 2013; 127:1128-1138.
21. Novartis Pharmaceuticals. Efficacy, Safety, Tolerability and Pharmacokinetics (pk) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH). Available at: https://clinicaltrials.gov/ct2/show/NCT01179737, accessed on April 20, 2015.
22. Al-Naamani N, Roberts KE, Hill NS, Preston IR. Imatinib as rescue therapy in a patient with pulmonary hypertension associated with Gaucher disease. Chest 2014; 146:e81-e83.
23. Ryczek R, Góra-Tybor J, Betkier-Lipińska K, Cwetsch A. Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma. Pol Merkur Lekarski 2013; 34:342-344.
24. Groeneveldt JA, Gans SJM, Bogaard HJ, Vonk-Noordegraaf A. Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition. Eur Respir J 2013; 42:869-870.
25. Patkowska E, Lech-Marańda E, Darocha S, et al. Reversible pulmonary arterial hypertension as a complication of dasatinib treatment, with efficacious and safe continuation of chronic myeloid leukaemia therapy with nilotinib. Hematologia 2013; 4:76-83.
26. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335:609-616.
27. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362:2260-2270.
28. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014; 123:494-500.
29. US Food and Drug Administration. FDA Adverse Event Reporting System. US Food and Drug Administration, Silver Spring, MD. Available at: http://www.fda.gov/cder/aers/default.htm, accessed in April 2014.
30. Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: Follow-up of phase 3 study. Blood 2014; 123:2317-2324.
31. Luo YF, Robbins IM, Karatas M, et al. Frequency of pleural effusions in patients with pulmonary arterial hypertension associated with connective tissue diseases. Chest 2011; 140:42-47.
32. Guignabert C, Montani D. Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed. Eur Respir J 2013; 41:3-4.
33. Kittipovanonth M, Bellavia D, Chandrasekaran K, et al. Doppler myocardial imaging for early detection of right ventricular dysfunction in patients with pulmonary hypertension. J Am Soc Echocardiogr 2008; 21:1035-1041.
34. Apfel HD, Shen Z, Gopal AS, et al. Quantitative three dimensional echocardiography in patients with pulmonary hypertension and compressed left ventricles: Comparison with cross sectional echocardiography and magnetic resonance imaging. Heart 1996; 76:350-354.